
|Articles|March 15, 2004
Drug beneficial for those with or without Sj?gren's dry eye
Anaheim, CA-Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) provides similar, significant improvement in the signs and symptoms of dry eye in both patients with keratoconjunctivitis sicca (KCS) associated with autoimmune disease and in those with non-Sj?gren's KCS, said Scott M. Whitcup, MD, at the annual meeting of the American Academy of Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
4
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
5















































.png)


